Evidence map›Paper›PMID 26663867›Full record

ReviewWiley interdisciplinary reviews. Nanomedicine and nanobiotechnology2016

Use of nanoparticles to deliver immunomodulatory oligonucleotides.

Dennis M Klinman, Takashi Sato, Takeshi Shimosato

Open access · greenAbstract readReview
In one paragraph

Review in Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Nanoparticle-allergen complexes for allergen immunotherapy.International journal of nanomedicine · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Dennis M KlinmanCancer and Inflammation Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Takashi SatoDepartment of Internal Medicine and Clinical Immunology, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Takeshi ShimosatoInterdisciplinary Graduate School of Science and Technology, Shinshu University, Kamiina, Japan.
Frederick National Laboratory for Cancer Research · USShinshu University · JPYokohama City University · JP

Funding

Mechanism of action and therapeutic utility of stimulatory CpG oligonucleotidesZIABC010852 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KLINMAN, DENNIS · 2009 to 2019
$11.3M
Mechanism of action and therapeutic utility of immunosuppressive oligonucleotideZIABC010853 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KLINMAN, DENNIS · 2009 to 2019
$3.8M
Mechanism of action and therapeutic utility of immunostimulatory CpG oligonucleoZ01BC010852 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KLINMAN, DENNIS · 2007 to 2008
$1.9M
Intramural NIH HHS Z01 BC010852
6 · The paper itself

Abstract

Synthetic oligonucleotides (ODNs) containing unmethylated 'CpG motifs' stimulate the innate immune system to produce cytokines, chemokines, and polyreactive antibodies. CpG ODNs have shown promise as vaccine adjuvants and for the treatment of infectious diseases and cancer. The immunostimulatory activity of CpG ODNs is inhibited by DNA-containing 'suppressive' motifs. ODNs expressing suppressive motifs (Sup ODNs) reduce ongoing immune reactions and show promise in the treatment of autoimmune and inflammatory diseases. This work reviews recent progress in the use of nanoparticles as carriers of CpG and Sup ODNs to target their delivery to the GI tract and lungs. WIREs Nanomed Nanobiotechnol 2016, 8:631-637. doi: 10.1002/wnan.1382 For further resources related to this article, please visit the WIREs website.

Indexed as

Drug CarriersImmunologic FactorsNanoparticlesOligonucleotidesAnimalsCpG IslandsHumansMiceNanomedicineNucleotide MotifsDrug CarriersImmunologic FactorsOligonucleotides

Identifiers

PMID26663867
PMCPMC4903938
OpenAlexW2190376258

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.